Brief: Vor Biopharma Inc Files For Mixed Shelf Offering Of Up To $350 Million
Brief: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
Vor Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Vor Bio Appoints Erez Kalir To Its Board Of Directors
U.S. RESEARCH ROUNDUP-Kratos Defense and Security Solutions, Masimo and Servicetitan
Vor Biopharma Inc reports results for the quarter ended in September 30 - Earnings Summary
Vor Biopharma Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: New Clinical Data Validates Vor Bio’S Approach Of Using Shielded Transplants
Vor Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Vor Biopharma Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vor Biopharma Inc - On June 4, 2024, Nathan Jorgensen Notified Co Of His Resignation As Chief Financial Officer Of Company, Effective As Of June 21
Vor Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Vor Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Vor Biopharma Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Vor Bio Doses First AML Patient with VCAR33
Vor Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Vor Biopharma Inc expected to post a loss of 43 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
Vor Biopharma up on positive data from blood cancer study